<DOC>
	<DOC>NCT01929655</DOC>
	<brief_summary>To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration</brief_summary>
	<brief_title>Japanese BAY88-8223 Monotherapy Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Have received docetaxel or not eligible for the first course of docetaxel, i.e. patients who are not fit enough and willing. Histologically or cytologically confirmed adenocarcinoma of the prostate Multiple bone metastases Either regular (not occasional) analgesic medication use for cancerrelated bone pain or treatment with external beam radiotherapy (EBRT) for bone pain. Best standard of care(BSoC) is regarded as the routine standard of care. Exclusion Criteria : Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period History of visceral metastasis, or presence of visceral metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase II</keyword>
	<keyword>symptomatic castration-resistant prostate cancer</keyword>
	<keyword>bone metastases</keyword>
</DOC>